<p>Xeris Biopharma（納斯達克：XERS - 獲取免費報告）預計將在 2025 年 8 月 7 日星期四市場開盤前發佈其 2025 年第二季度財報。分析師預計 Xeris Biopharma 本季度每股收益為（$0.03），收入為 6458 萬美元。Xeris Biopharma 已將其 2025 財年的指引設定為每股收益。</p>
<p>Xeris Biopharma（納斯達克：XERS - 獲取免費報告）最近一次發佈季度財報是在 5 月 8 日星期四。該公司報告本季度每股收益為（$0.06），超出分析師共識預期的（$0.07）$0.01。該公司本季度的收入為 5780 萬美元，而分析師預期為 5761 萬美元。分析師平均預計 Xeris Biopharma 在當前財年和下一個財年的每股收益均為$0。</p>
<p>獲取 <strong>Xeris Biopharma</strong> 警報：</p>
<h2>Xeris Biopharma 股價上漲 1.7%</h2>
<p>在週五的交易中，納斯達克 XERS 的股票上漲了$0.09，達到了$5.18。該公司交易了 616,563 股，較其平均交易量 2406861 股有所減少。該公司的 50 日簡單移動平均為$4.83，200 日簡單移動平均為$4.46。該股票的市值為 8.0927 億美元，市盈率為-17.15，貝塔值為 0.66。Xeris Biopharma 的 12 個月低點為$2.10，12 個月高點為$6.07。</p>
<h2>Xeris Biopharma 內部交易</h2>
<p>在其他新聞中，內部人士 Kevin Mcculloch 在 6 月 13 日星期五購買了 25,000 股該公司的股票。每股平均購買價格為$4.38，總價值為$109,500.00。交易完成後，該內部人士直接持有該公司 1,708,585 股股票，價值$7,483,602.30。這筆交易代表了他們持股比例的 1.48% 的增加。該交易已在證券交易委員會的備案中披露，相關文件可在此鏈接查看。目前，內部人士持有該股票的 6.47%。</p>
<h2>Xeris Biopharma 的機構交易</h2>
<p>一些機構投資者和對沖基金最近增加或減少了對該公司的持股。Acadian Asset Management LLC 在第一季度購買了 Xeris Biopharma 的新股份，價值$96,000。Caxton Associates LLP 在第一季度購買了 Xeris Biopharma 的新股份，價值$170,000。高盛集團在第一季度將其在 Xeris Biopharma 的持股增加了 75.4%。高盛集團目前持有該公司 2,790,014 股股票，價值$15,317,000，此前在該期間內又收購了 1,199,435 股。Millennium Management LLC 在第一季度將其在 Xeris Biopharma 的持股增加了 19.0%。Millennium Management LLC 目前持有該公司 2,317,972 股股票，價值$12,726,000，此前在該期間內又收購了 369,420 股。最後，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度將其在 Xeris Biopharma 的持股增加了 4.5%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有該公司 83,982 股股票，價值$461,000，此前在該期間內又收購了 3,594 股。對沖基金和其他機構投資者持有該公司 42.75% 的股份。</p>
<h2>分析師評級上調和下調</h2>
<p>幾位股票分析師最近對 XERS 股票發表了看法。華爾街 Zen 在 5 月 22 日星期四的研究報告中將 Xeris Biopharma 的評級從 “買入” 下調至 “持有”。Oppenheimer 在 5 月 9 日星期五的研究報告中將 Xeris Biopharma 的目標價從$6.00 上調至$7.00，並給予該股票 “跑贏大盤” 的評級。兩位分析師對該股票給予了持有評級，五位分析師對該公司的股票給予了買入評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，平均目標價為$6.25。</p>
<p><strong>閲讀我們關於 Xeris Biopharma 的最新報告</strong></p>
<h2>關於 Xeris Biopharma</h2>
<p>（獲取免費報告）</p>
<p>Xeris Biopharma Holdings, Inc 是一家生物製藥公司，專注於在伊利諾伊州開發和商業化療法。該公司提供 Gvoke，一種用於治療嚴重低血糖的即用型液體穩定胰高血糖素，適用於兒童和成人患者；Keveyis，一種用於治療高鉀血癥、低鉀血癥及相關類型的原發性週期性麻痹的療法；以及 Recorlev，一種用於治療庫欣綜合症成人患者內源性高皮質醇血癥的皮質醇合成抑制劑。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Xeris Biopharma</li>
<li>現在購買的三隻最佳藍籌股</li>
<li>Rocket Lab 下週報告：投資者需要知道的事項</li>
<li>低市盈率成長股：開啓投資機會</li>
<li>蘋果股票：大盈利，小波動——是時候買入了嗎？</li>
<li>如何開始投資房地產</li>
<li>亞馬遜的盈利：接下來會發生什麼以及如何應對</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVSUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVSUw"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Xeris Biopharma 嗎？</h2>
<p>在你考慮 Xeris Biopharma 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前買入……而 Xeris Biopharma 並不在其中。</p>
<p>雖然 Xeris Biopharma 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

XERS

<p>Xeris Biopharma (NASDAQ:XERS) 將於 2025 年 8 月 7 日星期四市場開盤前發佈其 2025 年第二季度財報。（查看財報請訪問 https://www.marketbeat.）</p>

<p>Xeris Biopharma (NASDAQ:XERS - Get Free Report) is anticipated to release its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect Xeris Biopharma to post earnings of ($0.03) per share and revenue of $64.58 million for the quarter. Xeris Biopharma has set its FY 2025 guidance at EPS.</p>
<div class="lb-trans"><p>Xeris Biopharma（納斯達克：XERS - 獲取免費報告）預計將在 2025 年 8 月 7 日星期四市場開盤前發佈其 2025 年第二季度財報。分析師預計 Xeris Biopharma 本季度每股收益為（$0.03），收入為 6458 萬美元。Xeris Biopharma 已將其 2025 財年的指引設定為每股收益。</p>
</div><p>Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The firm had revenue of $57.80 million for the quarter, compared to analyst estimates of $57.61 million. On average, analysts expect Xeris Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Xeris Biopharma（納斯達克：XERS - 獲取免費報告）最近一次發佈季度財報是在 5 月 8 日星期四。該公司報告本季度每股收益為（$0.06），超出分析師共識預期的（$0.07）$0.01。該公司本季度的收入為 5780 萬美元，而分析師預期為 5761 萬美元。分析師平均預計 Xeris Biopharma 在當前財年和下一個財年的每股收益均為$0。</p>
</div><p>Get <strong>Xeris Biopharma</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Xeris Biopharma</strong> 警報：</p>
</div><h2>Xeris Biopharma Trading Up 1.7%</h2>
<div class="lb-trans"><h2>Xeris Biopharma 股價上漲 1.7%</h2>
</div><p>Shares of NASDAQ XERS traded up $0.09 during trading on Friday, reaching $5.18. 616,563 shares of the company traded hands, compared to its average volume of 2,406,861. The firm's fifty day simple moving average is $4.83 and its 200 day simple moving average is $4.46. The stock has a market cap of $809.27 million, a P/E ratio of -17.15 and a beta of 0.66. Xeris Biopharma has a 12-month low of $2.10 and a 12-month high of $6.07.</p>
<div class="lb-trans"><p>在週五的交易中，納斯達克 XERS 的股票上漲了$0.09，達到了$5.18。該公司交易了 616,563 股，較其平均交易量 2406861 股有所減少。該公司的 50 日簡單移動平均為$4.83，200 日簡單移動平均為$4.46。該股票的市值為 8.0927 億美元，市盈率為-17.15，貝塔值為 0.66。Xeris Biopharma 的 12 個月低點為$2.10，12 個月高點為$6.07。</p>
</div><h2>Insider Transactions at Xeris Biopharma</h2>
<div class="lb-trans"><h2>Xeris Biopharma 內部交易</h2>
</div><p>In other news, insider Kevin Mcculloch bought 25,000 shares of the business's stock in a transaction on Friday, June 13th. The shares were bought at an average price of $4.38 per share, with a total value of $109,500.00. Following the completion of the transaction, the insider directly owned 1,708,585 shares in the company, valued at $7,483,602.30. This trade represents a 1.48% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. 6.47% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他新聞中，內部人士 Kevin Mcculloch 在 6 月 13 日星期五購買了 25,000 股該公司的股票。每股平均購買價格為$4.38，總價值為$109,500.00。交易完成後，該內部人士直接持有該公司 1,708,585 股股票，價值$7,483,602.30。這筆交易代表了他們持股比例的 1.48% 的增加。該交易已在證券交易委員會的備案中披露，相關文件可在此鏈接查看。目前，內部人士持有該股票的 6.47%。</p>
</div><h2>Institutional Trading of Xeris Biopharma</h2>
<div class="lb-trans"><h2>Xeris Biopharma 的機構交易</h2>
</div><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Acadian Asset Management LLC purchased a new stake in shares of Xeris Biopharma during the first quarter worth $96,000. Caxton Associates LLP purchased a new stake in shares of Xeris Biopharma during the first quarter worth $170,000. Goldman Sachs Group Inc. increased its position in shares of Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company's stock worth $15,317,000 after acquiring an additional 1,199,435 shares during the period. Millennium Management LLC increased its position in shares of Xeris Biopharma by 19.0% during the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company's stock worth $12,726,000 after acquiring an additional 369,420 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Xeris Biopharma by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company's stock worth $461,000 after acquiring an additional 3,594 shares during the period. Hedge funds and other institutional investors own 42.75% of the company's stock.</p>
<div class="lb-trans"><p>一些機構投資者和對沖基金最近增加或減少了對該公司的持股。Acadian Asset Management LLC 在第一季度購買了 Xeris Biopharma 的新股份，價值$96,000。Caxton Associates LLP 在第一季度購買了 Xeris Biopharma 的新股份，價值$170,000。高盛集團在第一季度將其在 Xeris Biopharma 的持股增加了 75.4%。高盛集團目前持有該公司 2,790,014 股股票，價值$15,317,000，此前在該期間內又收購了 1,199,435 股。Millennium Management LLC 在第一季度將其在 Xeris Biopharma 的持股增加了 19.0%。Millennium Management LLC 目前持有該公司 2,317,972 股股票，價值$12,726,000，此前在該期間內又收購了 369,420 股。最後，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度將其在 Xeris Biopharma 的持股增加了 4.5%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有該公司 83,982 股股票，價值$461,000，此前在該期間內又收購了 3,594 股。對沖基金和其他機構投資者持有該公司 42.75% 的股份。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調和下調</h2>
</div><p>Several equities analysts recently weighed in on XERS shares. Wall Street Zen lowered Xeris Biopharma from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, May 22nd. Oppenheimer boosted their price objective on Xeris Biopharma from $6.00 to $7.00 and gave the stock an &#34;outperform&#34; rating in a research note on Friday, May 9th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $6.25.</p>
<div class="lb-trans"><p>幾位股票分析師最近對 XERS 股票發表了看法。華爾街 Zen 在 5 月 22 日星期四的研究報告中將 Xeris Biopharma 的評級從 “買入” 下調至 “持有”。Oppenheimer 在 5 月 9 日星期五的研究報告中將 Xeris Biopharma 的目標價從$6.00 上調至$7.00，並給予該股票 “跑贏大盤” 的評級。兩位分析師對該股票給予了持有評級，五位分析師對該公司的股票給予了買入評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，平均目標價為$6.25。</p>
</div><p><strong>Read Our Latest Report on Xeris Biopharma</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Xeris Biopharma 的最新報告</strong></p>
</div><h2>About Xeris Biopharma</h2>
<div class="lb-trans"><h2>關於 Xeris Biopharma</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.</p>
<div class="lb-trans"><p>Xeris Biopharma Holdings, Inc 是一家生物製藥公司，專注於在伊利諾伊州開發和商業化療法。該公司提供 Gvoke，一種用於治療嚴重低血糖的即用型液體穩定胰高血糖素，適用於兒童和成人患者；Keveyis，一種用於治療高鉀血癥、低鉀血癥及相關類型的原發性週期性麻痹的療法；以及 Recorlev，一種用於治療庫欣綜合症成人患者內源性高皮質醇血癥的皮質醇合成抑制劑。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Xeris Biopharma</li>
<li>The 3 Best Blue-Chip Stocks to Buy Now</li>
<li>Rocket Lab Reports Next Week: Here’s What Investors Should Know</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>Apple Stock: Big Earnings, Small Move—Time to Buy?</li>
<li>How to Start Investing in Real Estate</li>
<li>Amazon's Earnings: What Comes Next and How to Play It</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Xeris Biopharma</li>
<li>現在購買的三隻最佳藍籌股</li>
<li>Rocket Lab 下週報告：投資者需要知道的事項</li>
<li>低市盈率成長股：開啓投資機會</li>
<li>蘋果股票：大盈利，小波動——是時候買入了嗎？</li>
<li>如何開始投資房地產</li>
<li>亞馬遜的盈利：接下來會發生什麼以及如何應對</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVSUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=XERS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Xeris Biopharma Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Xeris Biopharma 嗎？</h2>
</div><p>Before you consider Xeris Biopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Xeris Biopharma 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前買入……而 Xeris Biopharma 並不在其中。</p>
</div><p>While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Xeris Biopharma 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Xeris Biopharma (XERS) 預計將在週四宣佈財報